Vetmedin 2.5mg Capsules for Dogs

Country: New Zealand

Language: English

Source: Ministry for Primary Industries

Active ingredient:

pimobendan

Available from:

Boehringer Ingelheim Animal Health New Zealand Limited

INN (International Name):

pimobendan

Composition:

pimobendan 12.5 g/kg

Therapeutic area:

Cardiovascular agent

Authorization status:

ACVM Registered

Authorization date:

2000-06-12

Summary of Product characteristics

Product: Vetmedin 2.5 mg Capsules for Dogs
Date: 05 May 2022
ACVM No.: A007867
Page
1
of
6
BOTTLE LABEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Vetmedin
®
2.5 mg
Capsules for Dogs
Active Constituent:
Each capsule contains 2.5 mg Pimobendan
100 capsules
For the treatment of canine congestive heart failure originating from
dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid regurgitation).
READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT.
FIRST AID
If poisoning occurs, contact a doctor or Poisons Information Centre.
Phone Australia 131126. New Zealand 0800 764 766 (0800 POISON)
DISPOSAL
Dispose of empty container by wrapping in paper and putting in
garbage.
STORAGE
Store below 25 °C (Air Conditioning). Keep the container tightly
closed.
AUSTRALIA
Boehringer Ingelheim Animal Health Australia Pty Limited
Level 1
78 Waterloo Road
North Ryde NSW 2113
Phone: [phone]
APVMA 53561/XXXXX/XXXX
NEW ZEALAND INFORMATION
RVM
ACVM No. A007867
See www.foodsafety.govt.nz for registration conditions.
Boehringer Ingelheim Animal Health New Zealand Ltd
Level 3, 2 Osterley Way,
Manukau City,
Auckland 2104, New Zealand
Freephone: 0800 800 822
Batch No.:
Expiry Date:
Product: Vetmedin 2.5 mg Capsules for Dogs
Date: 05 May 2022
ACVM No.: A007867
Page
2
of
6
CARTON LABEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Vetmedin
®
2.5 mg
Capsules for Dogs
Active Constituent:
Each capsule contains 2.5 mg Pimobendan
100 capsules
INDICATIONS
Vetmedin
®
Capsules are indicated for:
The treatment of canine congestive heart failure (CHF) originating
from dilated
cardiomyopathy (DCM) or valvular insufficiency (mitral and/or
tricuspid regurgitation).
The treatment of preclinical DCM in large breed dogs. When used in
cases of preclinical DCM
in large breed dogs, pimobendan significantly prolonged the time to
the onset of CHF or
sudden death, and also resulted in prolongation of the time to death
due to all causes.
Doberman Pinscher dogs with